Received Mar 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | 2018414 | — |
HCP states patient has seen a "Significant" improvement in his (non-genital) warts after one dose of GARDASIL 9. No other informaiton provided. No additional AEs/PQC reported.; This spontaneous report was received from a nurse and refers to a 9-year-old male patient. The patient's medical history, concomitant therapies, drug reactions or allergies were not reported. The patient's concurrent conditions included (non-genital) warts. On 15-NOV-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) suspension for injection (valid lot number 2018414, expiration date: 11-DEC-2025) for prevention of human papillomavirus (HPV) (dose, dose number, vaccination scheme, anatomical location, route of administration were not provided). On 15-NOV-2024, the patient had seen a "significant" improvement in his (non-genital) warts after one dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (Therapeutic response unexpected). No other information provided. No additional adverse events reported. At the reporting time, the outcome of the event was not provided. The causal relationship between the event and Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) not reported.
Non-genital warts NOS